Welcome to our dedicated page for Tenax Therapeutics SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Tenax Therapeutics, Inc. (TENX) provides access to the company’s official disclosures as a Nasdaq-listed, Phase 3, development-stage pharmaceutical company. Through these filings, Tenax reports material events, clinical and corporate milestones, and periodic financial results related to its cardiopulmonary drug development programs.
Recent Form 8-K filings have documented key developments in the company’s PH-HFpEF program. These include announcements that the European Patent Office issued an Intention to Grant a patent covering TNX‑103 (oral levosimendan), other levosimendan formulations, and its active metabolites for use in PH-HFpEF, and that Tenax completed a prespecified blinded sample size re-estimation in the registrational Phase 3 LEVEL trial of TNX‑103 in the United States and Canada. Other 8‑K filings describe the initiation of the global Phase 3 LEVEL‑2 study and amendments to the company’s license agreement with Orion Corporation, expanding Tenax’s rights to develop, commercialize, and manufacture orally administered levosimendan products.
Filings also include earnings-related 8-Ks, where Tenax furnishes press releases detailing quarterly financial results and corporate updates. These disclosures discuss research and development spending on the LEVEL and LEVEL‑2 trials, general and administrative expenses, and the company’s cash position and funding outlook, all within the framework of SEC reporting requirements.
On this page, users can review Tenax’s SEC submissions, including current reports and other documents that may be filed over time. Stock Titan enhances this information with AI-powered summaries that explain the significance of complex filings, highlight clinical and IP milestones, and help readers quickly identify items related to Phase 3 trial progress, licensing arrangements, and the company’s PH-HFpEF strategy. This resource supports investors and researchers seeking a structured view of TENX’s regulatory and financial reporting history.
Tenax Therapeutics, Inc. (TENX) reported insider activity by its CEO and director, who bought common stock on three consecutive days. On 11/18/2025, the insider purchased 1,612 shares at a weighted average price of $7.7546, followed by 455 shares at $7.5091 on 11/19/2025 and 538 shares at $7.5887 on 11/20/2025. After these open‑market purchases, the insider beneficially owned 2,605 shares of Tenax common stock directly.
The filing also lists existing stock options held by the insider. These include options exercisable for 157 shares of common stock expiring on 07/06/2031, 125 shares expiring on 06/09/2032, and 437 shares expiring on 05/17/2034, along with larger grants for 1,250,000 shares at an exercise price of $5.94 expiring on 12/10/2034 and 1,400,000 shares at $5.89 expiring on 05/16/2035. The vesting of these options is tied to continued employment and follows specified annual or monthly schedules.
Tenax Therapeutics, Inc. (TENX) director reported open-market purchases of common stock and corrected how those shares are reported. On 11/17/2025, an indirect account bought 93 shares at $7.15 per share, and on 11/18/2025 it bought 1,900 shares at a weighted average price of $7.5157, for a total of 1,993 shares held through Meadowlark Management, LLC. This amended Form 4 changes the ownership form for those 1,993 shares from direct to indirect, clarifying that the director disclaims beneficial ownership beyond her economic interest.
Tenax Therapeutics (TENX) reported an insider stock purchase by its Interim CFO. On 11/17/2025, the officer bought 2,000 shares of common stock directly and now holds 2,000 shares in their own name. On the same date, they reported additional purchases of 1,000 shares held indirectly through a child and 5,000 shares held indirectly through a spouse.
The direct shares were acquired at a weighted average price of $7.337, with trades executed between $7.14 and $7.43. The spouse’s shares were bought at a weighted average price of $7.228, with trades between $7.17 and $7.30, and the child’s shares at $7.35. All transactions were coded as open-market purchases.
Tenax Therapeutics, Inc. (TENX) director reports open‑market share purchases. A company director filed a Form 4 disclosing two common stock purchases on 11/17/2025 and 11/18/2025. The director bought 93 shares at $7.15 per share and another 1,900 shares at a weighted average price of $7.5157, for a total of 1,993 common shares held directly after these trades. The filing also lists stock options giving the right to buy Tenax common stock, including 100,000 options at an exercise price of $5.94 exercisable from 12/10/2025 to 12/10/2034, and 80,000 options at an exercise price of $5.75 exercisable from 07/01/2026 to 07/01/2035, along with two smaller legacy option grants of 4 shares each.
Tenax Therapeutics (TENX) reported Q3 2025 results with a net loss of $15.8 million as it advanced Phase 3 programs. Operating expenses were $16.8 million, driven by research and development of $10.3 million and general and administrative of $6.5 million. Interest income was $1.0 million.
Liquidity remained strong with cash and cash equivalents of $99.4 million and working capital of $96.2 million as of September 30, 2025. Shares outstanding were 5,907,233 as of September 30, 2025; 6,243,575 were outstanding as of November 11, 2025. The company closed a March 2025 private placement for gross proceeds of $25.0 million.
Program and licensing updates: Tenax continues enrolling the Phase 3 LEVEL study and plans a second global Phase 3 (LEVEL‑2). A September 3, 2025 amendment with Orion expanded exclusive worldwide rights to orally administered levosimendan and set API supply terms. Prior amendments include a $10.0 million FDA approval milestone, a $5.0 million Japan approval milestone, and up to $45.0 million commercialization milestones.
Tenax Therapeutics (TENX) filed an 8-K stating it issued a press release announcing financial results for the third quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 and, as noted under Item 2.02, is not deemed “filed” for purposes of Section 18 of the Exchange Act. The company’s common stock trades on Nasdaq under the symbol TENX.
Tenax Therapeutics (TENX) disclosed that Ikarian Capital, LLC and Neil Shahrestani together report beneficial ownership of 967,600 shares of common stock, representing 21.2% of the outstanding class based on 4,562,500 shares outstanding. The reported position reflects shared voting and shared dispositive power over the 967,600 shares rather than sole control.
The holdings are held through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts for which Ikarian Capital acts as adviser; Mr. Shahrestani is identified as the ultimate controller of Ikarian Capital. The filing states the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
Tenax Therapeutics received a Schedule 13G disclosing that affiliated investment vehicles controlled by Raymond Debbane hold meaningful common stock positions. Invus Public Equities directly holds 366,143 shares, reported as 8.0% of the class, and Avicenna Life Sci Master Fund directly holds 60,998 shares, reported as 1.3%. Collectively, Mr. Debbane is reported as the beneficial owner of 427,141 shares, or 9.4%, based on an outstanding share count of 4,562,500 as reported by the issuer. The filing states these positions are not held to change or influence control of the company.
Tenax Therapeutics filed a report describing a new intellectual property development for its pulmonary hypertension program. On September 16, 2025, the company announced that the European Patent Office has issued an Intention to Grant a patent covering TNX-103 (oral levosimendan), other formulations of levosimendan, and its active metabolites for use in treating pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). This kind of protection helps define how long and how broadly Tenax can control use of this drug approach in that indication. The details are provided in a press release attached as an exhibit.
Tenax Therapeutics entered into an amendment to its long-standing license agreement with Orion Corporation covering levosimendan. The amendment grants Tenax exclusive worldwide rights to develop, commercialize, manufacture, and have manufactured any orally-administered pharmaceutical product containing levosimendan.
In addition to its existing rights for subcutaneously administered levosimendan products, Tenax now also gains rights to manufacture or have manufactured those subcutaneous products. Orion will supply Tenax with levosimendan for orally-administered products under agreed terms, including pricing in the low triple-digit thousands in Euros per kilogram and defined payment and active ingredient specifications.